Researchers discover that allergy-driving protein influences signal transmission in the brain

September 13, 2018, University of Bonn
Top: CCL17-producing neurons (green) and microglia (red) in the hippocampus. Bottom: Reconstruction of an individual microglia cell from wild-type or CCL17-knockout mice. Credit: Lorenz Fülle/Uni Bonn

The chemotactic protein CCL17 attracts immune cells to where they are needed. Doctors have long known that a high level of CCL17 in the body indicates an allergic reaction. Researchers led by the University of Bonn have now discovered a completely new function: CCL17 also influences signal transmission in the brain. There may even be a molecular link to autism. The results have now been published in the journal Glia.

Chemotactic cytokines, chemokines for short, are signaling proteins that act as attractants and ensure that migrate from the bloodstream into the tissues, for example. The chemokine CCL17 is known to increase inflammation and is associated with allergic diseases. A high level of CCL17 in the blood is regarded by doctors as a diagnostic marker of ongoing such as atopic eczema. An earlier joint study by the Universities of Münster and Bonn showed that animals with a defect in the expression of the receptor for CCL17 have behavioral problems. For example, they were unable to build proper nests like their normally developed mates.

"These behavioral changes indicated that CCL17 not only affects the immune system, but perhaps also the brain," says corresponding author Prof. Dr. Irmgard Förster from the LIMES Institute at the University of Bonn. The researchers wondered which cells in the brain produce CCL17. This issue was investigated by doctoral student Lorenz Fülle and Irmgard Förster, together with scientists from the Institute of Cellular Neurosciences around Prof. Dr. Christian Henneberger, Dr. Annett Halle from the German Center for Neurodegenerative Diseases (DZNE) and Dr. Judith Alferink from the University of Münster.

Through a genetic modification, the researchers coupled the release of CCL17 with the production of a fluorescent dye that illuminated all cells that produce the chemokine. The scientists additionally stimulated CCL17 production by simulating an infection using a substance contained in bacterial cell membranes. The production sites of the chemokine in the brain were then clearly visible under the microscope. "CCL17 is mainly produced by neurons of the hippocampus," reports lead author Lorenz Fülle. This structure, which is shaped like a seahorse, is present on the right and left side of the brain, and fulfills an important function in tasks such as orientation and memory formation.

(From left): Nina Offermann, Lorenz Fülle and Prof. Dr. Irmgard Förster. Credit: © Barbara Frommann/Uni Bonn

As a next step, the scientists blocked the gene for CCL17 production and observed the effect. In the absence of the chemokine, the in these "knockout" mice were significantly smaller and there were only half as many as in untreated control animals. Microglial cells have long been known as immune cells of the brain, where they take responsibility as "health guards" for the disposal of cell debris and infectious agents. Meanwhile, it has been shown that these "scavenger cells" also directly support the work of the neurons independently of their phagocytic activity.

In order to investigate the effect of CCL17 on the function of neurons, scientists in the laboratory of Prof. Dr. Christian Henneberger at the Institute of Cellular Neurosciences (University of Bonn Medical School) examined neuronal signaling in the brain. Henneberger says, "The experiments indicate that CCL17 attenuates signal transmission in the hippocampal region of the ." Since autism in humans is also associated with elevated levels of CCL17 in the blood, CCL17 could also play a role in this developmental disorder, for example, due to an infection or an allergic reaction in early childhood. "But so far these are speculations," says Förster. "The exact effects of CCL17 have yet to be demonstrated by further research."

Explore further: Newly identified drug target in rheumatoid arthritis paves way for development of new therapies

More information: Lorenz Fülle et al, CCL17 exerts a neuroimmune modulatory function and is expressed in hippocampal neurons, Glia (2018). DOI: 10.1002/glia.23507

Related Stories

Newly identified drug target in rheumatoid arthritis paves way for development of new therapies

August 22, 2018
University of Melbourne researchers have identified a protein involved in rheumatoid arthritis-induced inflammation that could lead to new drug treatments for people who do not respond to current therapies.

New approach for treatment of contact allergy

October 30, 2017
Researchers from the University of Bonn have isolated a molecule that is suitable for the control of contact allergies. The study illuminates a central immune mechanism, which may also play a role in other inflammatory diseases ...

Fast track to vascular disease

June 3, 2011
In Western societies, atherosclerosis of the arteries is one of the leading causes of death. Chronic, localized inflammation of the blood vessel wall facilitates the growth of fibrous plaques, which leads to narrowing or ...

Vicious circle leads to loss of brain cells in old age

September 4, 2018
The so-called CB1 receptor is responsible for the intoxicating effect of cannabis. However, it also appears to act as a kind of "sensor" with which neurons measure and control the activity of certain immune cells in the brain. ...

Seasonal allergies could change your brain

August 8, 2016
Hay fever may do more than give you a stuffy nose and itchy eyes, seasonal allergies may change the brain, says a study published in the open-access journal Frontiers in Cellular Neuroscience.

HIV lies dormant in brain, increasing risk of dementia, but how?

May 23, 2018
The HIV virus, which causes AIDS, has long been known to target and disable cells of the immune system, which are responsible for fighting off invading microorganisms and for suppressing malignant cancers. More recently, ...

Recommended for you

New insights into how an ordinary stem cell becomes a powerful immune agent

November 19, 2018
How do individual developing cells choose and commit to their "identity"—to become, for example, an immune cell, or a muscle cell, or a neuron?

New inflammation inhibitor discovered

November 16, 2018
A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action. By inhibiting a certain protein, the researchers were able ...

Pets can double as asthma antidote

November 16, 2018
(HealthDay)—The "hygiene hypothesis" holds that early exposure to a variety of microorganisms may decrease the risk for chronic inflammatory diseases, like asthma.

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Defense against intestinal infection in organism is affected by prostaglandin E2

November 15, 2018
The treatment of intestinal infections caused by some strains of the bacterium Escherichia coli, present in unsanitized or contaminated foods, may have a new ally.

No link between 'hypoallergenic' dogs and lower risk of childhood asthma

November 15, 2018
Growing up with dogs is linked to a lower risk of asthma, especially if the dogs are female, a new study from Karolinska Institutet and Uppsala University in Sweden shows. However, the researchers found no relation between ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.